Gossamer Bio, Inc. (GOSS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US38341P1021
Gossamer Bio, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 48.47 m USD |
| Operating income | -170.73 m USD |
| EBIT | -161.44 m USD |
| Net income | -170.37 m USD |
| Diluted EPS – continuing operations | -0.75 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
More stocks
- FEDERAL AGRICULTURAL MORTGAGE CORP (AGM)
- TSE Co. Ltd (131290.KQ)
- Investis Holding SA (IREN.SW)
- SEOUL GUARANTEE INSURANCE (031210.KS)
- Northwest Bancshares, Inc. (NWBI)
- Chicony Electronics Co Ltd (2385.TW)
- OC Oerlikon Corporation AG Pfaeffikon (OERL.SW)
- AF Gruppen ASA (AFG.OL)
- Addus HomeCare Corp (ADUS)
- Tonghua Dongbao Pharmaceutical Co Ltd (600867.SS)
- Shanghai Suochen Information Technology Co. Ltd. A (688507.SS)
- Shenyang Jinshan Energy Co Ltd (600396.SS)
Not investment advice. All data without warranty, price as of 27.10.2026. Details in the risk notice.